---
title: "Hong Kong Stock Market News | WUXI BIO opens nearly 4% higher, raises this year's project guidance, and reaches an agreement with BioNTech SE."
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/105874800.md"
description: "WUXI BIO opened nearly 4% higher, and as of the time of writing, it has risen by 3.78% to HKD 31.6, with a turnover of HKD 130 million. In terms of news, WUXI BIO recently released a PPT at the JPMorgan Healthcare Conference, disclosing that the company added 132 new projects last year, bringing the total number of projects to 698. The company is confident in achieving steady growth this year, with the target for the number of new projects in 2024 increased from 80 to 110. In addition, the company announced a research service agreement between its Contract Research and Development Organization (CRDMO) and BioNTech SE SE, to develop antibodies targeting two undisclosed targets for the development of next-generation candidate drugs. WUXI BIO will receive an initial payment of USD 20 million and will be eligible for research, development, registration, and commercialization milestone payments, as well as tiered sales royalties."
datetime: "2024-01-12T01:30:12.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/105874800.md)
  - [en](https://longbridge.com/en/news/105874800.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/105874800.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/105874800.md) | [繁體中文](https://longbridge.com/zh-HK/news/105874800.md)


# Hong Kong Stock Market News | WUXI BIO opens nearly 4% higher, raises this year's project guidance, and reaches an agreement with BioNTech SE.

Zhitong App learned that WUXI BIO (02269) opened nearly 4% higher. As of the time of writing, it has risen by 3.78% to HKD 31.6, with a turnover of HKD 130 million.

In terms of news, WUXI BIO recently released a PPT at the JPMorgan Healthcare Conference, disclosing that the company added 132 new projects last year, bringing the total number of projects to 698. The company is confident in achieving steady growth this year, with the target for the number of new projects in 2024 raised from 80 to 110.

In addition, the company announced a research service agreement between its Contract Research and Development Organization (CRDMO) and BioNTech SE SE, aiming to develop next-generation candidate drugs targeting two undisclosed targets. WUXI BIO will receive an upfront payment of USD 20 million and will be eligible for research, development, registration, and commercialization milestone payments, as well as tiered sales royalties.

### Related Stocks

- [WUXI BIO (02269.HK)](https://longbridge.com/en/quote/02269.HK.md)
- [BioNTech SE (BNTX.US)](https://longbridge.com/en/quote/BNTX.US.md)
- [WuXi Biologics (Cayman) Inc. (WXXWY.US)](https://longbridge.com/en/quote/WXXWY.US.md)

## Related News & Research

- [Reeves’s stranglehold on the economy is tightening](https://longbridge.com/en/news/281316009.md)
- [Guan Chao's Loss Balloons in 2025](https://longbridge.com/en/news/281314987.md)
- [Eni, European Investment Bank Sign 500 Million Euro Loan for New Biorefinery](https://longbridge.com/en/news/281380703.md)
- [Starfighters Space Delays Annual 10-K Filing](https://longbridge.com/en/news/281397627.md)
- [TSMC's Supply Squeeze Through 2028 Could Be This Chipmaker's Big Break As AI Demand From Nvidia, Apple Surges](https://longbridge.com/en/news/281141442.md)